- Home
- SRZN vs IGI Comparison
SRZN vs IGI Comparison
Compare SRZN & IGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRZN
- IGI
- Stock Information
- Founded
- SRZN 2015
- IGI 2009
- Country
- SRZN United States
- IGI United States
- Employees
- SRZN N/A
- IGI N/A
- Industry
- SRZN Medicinal Chemicals and Botanical Products
- IGI Investment Managers
- Sector
- SRZN Health Care
- IGI Finance
- Exchange
- SRZN Nasdaq
- IGI Nasdaq
- Market Cap
- SRZN 117.8M
- IGI 102.0M
- IPO Year
- SRZN N/A
- IGI N/A
- Fundamental
- Price
- SRZN $13.23
- IGI $16.35
- Analyst Decision
- SRZN Strong Buy
- IGI
- Analyst Count
- SRZN 2
- IGI 0
- Target Price
- SRZN $38.50
- IGI N/A
- AVG Volume (30 Days)
- SRZN 92.5K
- IGI 33.9K
- Earning Date
- SRZN 11-07-2025
- IGI 01-01-0001
- Dividend Yield
- SRZN N/A
- IGI 4.79%
- EPS Growth
- SRZN N/A
- IGI N/A
- EPS
- SRZN N/A
- IGI N/A
- Revenue
- SRZN $3,604,000.00
- IGI N/A
- Revenue This Year
- SRZN N/A
- IGI N/A
- Revenue Next Year
- SRZN N/A
- IGI N/A
- P/E Ratio
- SRZN N/A
- IGI N/A
- Revenue Growth
- SRZN N/A
- IGI N/A
- 52 Week Low
- SRZN $5.90
- IGI $15.13
- 52 Week High
- SRZN $18.17
- IGI $17.79
- Technical
- Relative Strength Index (RSI)
- SRZN 51.18
- IGI 33.21
- Support Level
- SRZN $12.12
- IGI $16.33
- Resistance Level
- SRZN $14.18
- IGI $16.43
- Average True Range (ATR)
- SRZN 0.75
- IGI 0.10
- MACD
- SRZN 0.06
- IGI -0.01
- Stochastic Oscillator
- SRZN 61.92
- IGI 12.96
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
About IGI Western Asset Investment Grade Defined Opportunity Trust Inc.
Western Asset Invstm Grd Dfnd Opp Tr Inc operates as a non-diversified closed-end management investment company. Its primary investment objective is to provide current income and then liquidate & distribute substantially all of the Fund's net assets to stockholders. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing at least 80% of its net assets in investment-grade corporate fixed-income securities of varying maturities.